Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2015 / Dec / Mission: Impossible
Oncology Oncology

Mission: Impossible

Pancreatic cancer is tough to understand, diagnose and treat. Undeterred researchers are on a quest to crack the case.

By Michael Schubert, Christopher Chapman 12/20/2015 1 min read

Share

Although only the 12th most common cancer worldwide (1), pancreatic cancer has gained increasing attention over the last few years. High-profile figures like Steve Jobs and Randy Pausch have shone a bright spotlight on the disease, but despite the increase in research interest, progress remains slow. Why? A combination of factors: the potential causes of the disease are not well understood, screening techniques are imperfect, chemotherapy and radiation treatments have limited success, and the mortality rate is high – only about 6 percent of patients survive five years (2), and that number drops to 1 percent after 10 years (3). But these are not just dismal statistics – they are a call to arms for researchers, and lately, that call has been answered extensively, with new ideas for diagnosis, prognosis and treatment seeming to arrive every day. In this series of articles, we speak with some of those scientists at the forefront of this research to learn more about what’s being done. Will we soon see those survival statistics improve? It’s still early days for the new wave of pancreatic cancer breakthroughs, but one thing’s for sure – the promise is most certainly there.

Tapping a Rich Vein by Christopher Chapman

New Ab-ilities in Imaging by Michael Schubert

Surprising Subtypes by Michael Schubert

Friend or Foe? by Anne Marie Lennon

(Chemo)resistance Is Futile by Michael Schubert

Breaching Cancer’s Defenses by Ingunn Stromnes

An Epigenetic Epiphany by Michael Schubert

Building a Better Mousetrap by Michael Schubert

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. J Ferlay et al. “GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11”, (2013). Available at: http://globocan.iarc.fr. Accessed November 23, 2015. M Sant et al., “EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary”, Eur J Cancer, 45, 931–991 (2009). PMID: 19171476. Cancer Research UK, “One-, five- and ten-year survival for pancreatic cancer”, (2014). Available at: http://bit.ly/21d4tyO. Accessed November 23, 2015.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Christopher Chapman

Christopher Chapman is a gastroenterology fellow at the University of Chicago Hospitals, Chicago, USA.

More Articles by Christopher Chapman

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.